Hypoxia-induced paclitaxel resistance in cervical cancer modulated by miR-100 targeting of USP15

Nishi, Hirotaka; Ono, Masahiro; Ohno, Shinya; Yamanaka, Zenta; Sasaki, Toru; Ohyashiki, Kazuma; Ohyashiki, Junko H.; Kuroda, Masahiko

doi:10.1016/j.gore.2023.101138

Cited by 2 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inclusion of patients in this study who had not previously undergone antitumor therapy may have contributed to the slightly more favorable results compared to related studies. Thus, it is conceivable that previous antitumor therapy could have induced local fibrosis, thereby impeding the direct targeting of local tumor cells by chemotherapeutic drugs and potentially diminishing the effectiveness of chemotherapy [27][28][29][30].…”

Section: Discussionmentioning

confidence: 99%

Comparison of the clinical efficacy of paclitaxel + carboplatin and paclitaxel + cisplatin on tumor markers and WHOQOL-BREF score on cervical cancer patients

2023

EJGO

View full text Add to dashboard Cite

This study aims to compare tumor marker indicators, World Health Organization Quality of Life-Brief assessment (WHOQOL-BREF) scores and clinical outcomes between cervical cancer patients treated with paclitaxel + carboplatin versus those treated with paclitaxel + cisplatin. 66 cervical cancer patients admitted to our hospital were randomly selected and allocated equally into a control group (paclitaxel + cisplatin) and a study group (paclitaxel + carboplatin) using a randomized double-blinded approach. Tumor marker indices, WHOQOL-BREF scores, Karnofsky Performance Status (KPS) scores, clinical outcomes and adverse effects were assessed and compared before and after treatment. The study group was found to have lower carcino-embryonic antigen (CEA), Carbohydrate antigen (CA) 199, CA125 and CA50 levels, significantly higher WHOQOL-BREF scores, and significantly higher KPS scores at 7 days, 1 month, 2 months and 3 months post-treatment compared to the control group (all p < 0.05). However, we also observed that while the treatment effectiveness rate in the study group (75.76%) surpassed that in the control group (66.67%), the difference was statistically significant (p > 0.05). Patients in the study group had a statistically significant lower incidence of diarrhea (45.45%) and nausea and vomiting (48.48%) compared to the control group, whose corresponding rates were higher at 69.70% and 75.76%, respectively (χ 2 = 3.969, 5.215, p = 0.046, 0.022). Conversely, the incidence of bone marrow suppression in the study group (48.48%) was significantly higher than that in the control group (21.21%) (χ 2 = 4.405, p = 0.020). We conclude that the combination of paclitaxel and carboplatin was an effective treatment approach for cervical cancer patients, offering comparative advantages over paclitaxel + cisplatin, with reduced tumor marker levels, enhanced quality of life, and minimized adverse reaction occurrence.

show abstract

Section: Discussionmentioning

confidence: 99%